ESTRO Multidisciplinary Management of Breast Cancer 2017

Meta-analysis Stuart et al: 10 yr Ipsilateral Breast Recurrence

All

Subset NOT receiving Tam

Subset also receiving Tamoxifen

Mastectomy 2.6% Lumpectomy + RT 13.6% 14.1% (7.2% invasive)

9.7%

Lumpectomy - RT 25.5% 25.1% (11.3% invasive) 24%

Biopsy only

27.8%

2 adjuvant Rx significantly less invasive LR than one or none adjuvant Rx